Objective To evaluate the efficacy and safety of xanomeline-trospium vs placebo in adults with schizophrenia. Design, Setting, and Participants EMERGENT-3 (NCT04738123) was a phase 3, multicenter, randomized, double-blind, placebo-controlled, 5-week trial of xanomeline-trospium in people with ...
C. et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 54, 465–473. https://doi.org/10.1001/archneur.1997.00550160091022 (1997). 19. Thal, D. M....
Efficacy and Safety of Xanomeline, a M1/M4 Receptor Preferencing Agonist, Plus Trospium, a Peripheral Muscarinic Antagonist, in Schizophrenia: Phase 2 Clinical Trial Resultsdoi:10.1016/j.biopsych.2020.02.446Stephen BrannanSharon SawchakAndrew Miller...
1995 (3)Bodick NC, Offen W. S-16-4 xanomeline: The first study of the safety and efficacy of an m1 agonist in mild and moderate alzheimer's disease. Eur Neuropsychopharm 1995; 5: 205 [DOI: 10.1016/0924-977X(95)90228-6]
In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline and trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia and was generally well tolerated. We ...
Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophreniadoi:10.1016/j.nsa.2024.104220K. KramerI. KaulE. CohenA. ClaxtonS. BrannanMicroelectronics Journal
R. Cutler. Efficacy of xanomeline in Alzheimer's disease: cognitive improvement measured using the computerized neuropsycho- logical test battery (CNTB). Alzheimer Dis. Assoc. Disord. 12:304Y312 (1998).Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR (1998) Efficacy of xanomelin...
KarXT is designed to preserve xanomeline's beneficial central nervous system effects while mitigating side effects due to peripheral muscarinic receptor activation. The efficacy and safety of KarXT in schizophrenia were demonstrated in the 5-week, randomized, double-blind, placebo-...
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED EMERGENT TRIALSKarXTmuscarinic receptorsschizophreniaxanomelineBackground: A high unmet medical need exists for more effective, better tolerated treatments for schizophrenia w...
Potency and efficacy of agonists carbachol, oxotremorine, pilocarpine and xanomeline of intracellular calcium response.Eva, ŠantrůčkováVladimír, DoležalEsam, E. ElFakahanyJan, Jakubík